abstract：BACKGROUND:We evaluated the influence of serum cystatin C (CysC) with respect to other glomerular filtration rate (GFR) markers on the treatment effect of everolimus in a phase II study in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS:Outcomes were from the study's primary analysis. GFR w...

journal_title：Cancer chemotherapy and pharmacology

authors： Bodnar L,Stec R,Dzierżanowska M,Synowiec A,Cierniak S,Kade G,Szczylik C

更新日期：2016-08-01 00:00:00

abstract：BACKGROUND:Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics. METHODS:Rich and sparse bevacizumab serum concentrations were collected from Phase I through IV studies in early a...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Peyret T,Marchand M,Quartino A,Gosselin NH,Girish S,Allison DE,Jin J

更新日期：2016-08-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

journal_title：Cancer chemotherapy and pharmacology

authors： Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

更新日期：2016-07-01 00:00:00

abstract：PURPOSE:To describe the natural growth of vestibular schwannoma in patients with neurofibromatosis type 2 and to predict tumor volume evolution in patients treated with bevacizumab and everolimus. METHODS:Clinical data, including longitudinal tumor volumes in patients treated by bevacizumab (n = 13), everolimus (n = 7...

journal_title：Cancer chemotherapy and pharmacology

authors： Ouerdani A,Goutagny S,Kalamarides M,Trocóniz IF,Ribba B

更新日期：2016-06-01 00:00:00

abstract：PURPOSE:Since the hypothesis that solid tumors cause angiogenesis by secreting pro-angiogenic factors was introduced, research on angiogenesis has proceeded continuously. Development of inhibitors targeting the angiogenic tyrosine kinases, to block downstream signal transduction pathways, has become an important approa...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang J,Zhang L,Wang Y,Zhao G

更新日期：2016-05-01 00:00:00

abstract：PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

journal_title：Cancer chemotherapy and pharmacology

authors： Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

更新日期：2016-05-01 00:00:00

abstract：PURPOSE:This study compared the pharmacokinetics of PF-06439535, a potential bevacizumab biosimilar, to bevacizumab sourced from the European Union (bevacizumab-EU) and USA (bevacizumab-US), and of bevacizumab-EU to bevacizumab-US. METHODS:In this double-blind study, 102 healthy males, aged 21-55 years, were randomize...

journal_title：Cancer chemotherapy and pharmacology

authors： Knight B,Rassam D,Liao S,Ewesuedo R

更新日期：2016-04-01 00:00:00

abstract：PURPOSE:This study characterized the pharmacokinetics, mass balance, routes and extent of elimination, metabolites, and safety of a single oral dose of (14)C-linsitinib, an IGF-1R/IR inhibitor, in patients with advanced solid tumors. The tolerability of linsitinib after multiple-dose administration was assessed in thos...

journal_title：Cancer chemotherapy and pharmacology

authors： Poondru S,Chaves J,Yuen G,Parker B,Conklin E,Singh M,Nagata M,Gill S

更新日期：2016-04-01 00:00:00

abstract：PURPOSE:Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to characterize PK, determine variability, and estimate covariate e...

journal_title：Cancer chemotherapy and pharmacology

authors： Goel V,Hurh E,Stein A,Nedelman J,Zhou J,Chiparus O,Huang PH,Gogov S,Sellami D

更新日期：2016-04-01 00:00:00

abstract：:In the original article, corresponding author's given name and family name are flipped. It should be "Siqing Fu" rather than "Fu Siqing". ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fu S,Culotta KS,Falchook GS,Hong DS,Myers AL,Zhang YP,Naing A,Janku F,Hou MM,Kurzrock R

更新日期：2016-04-01 00:00:00

abstract：PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

更新日期：2016-03-01 00:00:00

abstract：:Brain tumor lacks effective delivery system for treatment. Focused ultrasound (FUS) can reversibly open BBB without impacts on normal tissues. As a potential drug carrier, cationic liposomes (CLs) have the ability to passively accumulate in tumor tissues for their positive charge. In this study, FUS introduced doxorub...

journal_title：Cancer chemotherapy and pharmacology

authors： Lin Q,Mao KL,Tian FR,Yang JJ,Chen PP,Xu J,Fan ZL,Zhao YP,Li WF,Zheng L,Zhao YZ,Lu CT

更新日期：2016-02-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA, with a 5-year survival rate of 6 %. Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and ...

journal_title：Cancer chemotherapy and pharmacology

authors： De Souza A,Khawaja KI,Masud F,Saif MW

更新日期：2016-02-01 00:00:00

abstract：BACKGROUND:Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal ade...

journal_title：Cancer chemotherapy and pharmacology

authors： Eads JR,Beumer JH,Negrea L,Holleran JL,Strychor S,Meropol NJ

更新日期：2016-02-01 00:00:00

abstract：PURPOSE:The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP). METHODS:Previously unt...

journal_title：Cancer chemotherapy and pharmacology

authors： Shin DY,Choi YH,Lee HR,Na II,Yuh YJ,Kim BS,Chung IJ,Bae WK,Shim HJ,Song EK,Yang SH,Kang HJ

更新日期：2016-01-01 00:00:00

abstract：PURPOSE:The study mainly aimed to determine the biological function of a novelly synthesized phenanthroimidazole derivative, named L233, and to explore its potential mechanisms. METHODS:Cell survival was examined using the MTT assays, and the DNA-damaging role of L233 was explored using the comet assay. Moreover, the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhen N,Yang Q,Wu Q,Zhu X,Wang Y,Sun F,Mei W,Yu Y

更新日期：2016-01-01 00:00:00

abstract：PURPOSE:Evodiamine is one of active alkaloids isolated from the traditional Chinese medicine Evodia rutaecarpa Bentham and has various pharmacological properties. In this study, we investigated its effects on the migration, invasion, and associated mechanism in human nasopharyngeal carcinoma (NPC) cells. METHODS:Cell ...

journal_title：Cancer chemotherapy and pharmacology

authors： Peng X,Zhang Q,Zeng Y,Li J,Wang L,Ai P

更新日期：2015-12-01 00:00:00

abstract：PURPOSE:The prognosis of gastroesophageal cancer is poor, and current regimens are associated with limited efficacy. The purpose of this study was to explore the safety and preliminary efficacy of docetaxel, oxaliplatin plus capecitabine for advanced cancer of the stomach or the gastroesophageal junction (GEJ). Seconda...

journal_title：Cancer chemotherapy and pharmacology

authors： Deenen MJ,Meulendijks D,Boot H,Legdeur MC,Beijnen JH,Schellens JH,Cats A

更新日期：2015-12-01 00:00:00

abstract：PURPOSE:Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarker...

journal_title：Cancer chemotherapy and pharmacology

authors： Shinke H,Masuda S,Togashi Y,Ikemi Y,Ozawa A,Sato T,Kim YH,Mishima M,Ichimura T,Bonventre JV,Matsubara K

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

journal_title：Cancer chemotherapy and pharmacology

authors： Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bulten BF,Verberne HJ,Bellersen L,Oyen WJ,Sabaté-Llobera A,Mavinkurve-Groothuis AM,Kapusta L,van Laarhoven HW,de Geus-Oei LF

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:To evaluate the effect of renal impairment on eribulin mesylate pharmacokinetics following a single dose in adults with advanced solid tumors. METHODS:Patients were grouped by renal function: moderate impairment (creatinine clearance [CrCl] 30-50 mL/min), severe impairment (CrCl 15-29 mL/min), or normal (CrCl ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tan AR,Sarantopoulos J,Lee L,Reyderman L,He Y,Olivo M,Goel S

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:To characterize cobimetinib pharmacokinetics and evaluate impact of clinically relevant covariates on cobimetinib pharmacokinetics. METHODS:Plasma samples (N = 4886) were collected from 487 patients with various solid tumors (mainly melanoma) in three clinical studies (MEK4592g, NO25395, GO28141). Cobimetinib ...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Jin JY,Marchand M,Eppler S,Choong N,Hack SP,Tikoo N,Bruno R,Dresser M,Musib L,Budha NR

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA-mutated cancer. This Phase I, open-label, three-part study (Parts A-C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of olaparib when administered in tablet formulation. METHODS:PK d...

journal_title：Cancer chemotherapy and pharmacology

authors： Plummer R,Swaisland H,Leunen K,van Herpen CM,Jerusalem G,De Grève J,Lolkema MP,Soetekouw P,Mau-Sørensen M,Nielsen D,Spicer J,Fielding A,So K,Bannister W,Molife LR

更新日期：2015-10-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate the efficacy and toxicity of cetuximab and pemetrexed as the second-line treatment for advanced esophageal cancer patients, who had undergone treatment with the standard cisplatin and 5-FU regimens. METHODS:A total of 29 patients accepted this treatment. Cetuximab was admi...

journal_title：Cancer chemotherapy and pharmacology

authors： Tian J,Shang M,Shi SB,Han Y,Xu J

更新日期：2015-10-01 00:00:00

abstract：PURPOSE:5-Fluorouracil is the most commonly used drug for the treatment of colon cancer, yet clinical resistance to this drug is frequently observed in patients making this drug ineffective. Thus, identification of gene responsible for 5-FU resistance is of utmost importance. METHODS:Cellular cytotoxicity and expressi...

journal_title：Cancer chemotherapy and pharmacology

authors： Das D,Satapathy SR,Siddharth S,Nayak A,Kundu CN

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). METHODS:A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Enomoto Y,Inui N,Imokawa S,Karayama M,Hasegawa H,Ozawa Y,Matsui T,Yokomura K,Suda T

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

更新日期：2015-09-01 00:00:00

abstract：PURPOSE:The aims of this dose-escalating phase I study were to determine the maximum tolerable dose (MTD) and recommended dose (RD) of 5-fluorouracil (5-FU), docetaxel, and nedaplatin (UDON) combination therapy for future phase II studies, and to evaluate the safety and efficacy of this regimen in patients with untreat...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueda S,Kawakami H,Nishina S,Sakiyama T,Nonagase Y,Okabe T,Tamura T,Nakagawa K

更新日期：2015-08-01 00:00:00

abstract：PURPOSE:To determine the maximum recommended dose (RD) and pharmacokinetics of Myocet®, a non-pegylated liposomal doxorubicin, in children. METHODS:Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. Cohorts of at least three pat...

journal_title：Cancer chemotherapy and pharmacology

authors： Chastagner P,Devictor B,Geoerger B,Aerts I,Leblond P,Frappaz D,Gentet JC,Bracard S,André N

更新日期：2015-08-01 00:00:00

abstract：:Erratum to: Cancer Chemother Pharmacol (2014), 74:1139–1147, DOI 10.1007/s00280‑014‑2586‑6. Unfortunately, the part of acknowledgement detail was omitted in the published article and the below line must be considered as the last sentence: "This study is a Turkish Oncology Group trial". ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ozdemir N,Abali H,Vural M,Yalcin S,Oksuzoglu B,Civelek B,Oguz D,Bostanci B,Yalcin B,Zengin N

更新日期：2015-07-01 00:00:00

abstract：PURPOSE:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are key drugs in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR activating mutations. We assessed the efficacy and safety of one EGFR tyrosine kinase inhibitor, erlotinib, in elderly Japanese patients with EGFR-mutated NSCLC....

journal_title：Cancer chemotherapy and pharmacology

authors： Inoue Y,Inui N,Asada K,Karayama M,Matsuda H,Yokomura K,Koshimizu N,Imokawa S,Yamada T,Shirai T,Kasamatsu N,Suda T

更新日期：2015-07-01 00:00:00

abstract：PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

journal_title：Cancer chemotherapy and pharmacology

authors： Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

更新日期：2015-07-01 00:00:00

abstract：PURPOSE:The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between these drugs. According to our phase I study, the combination of capecitabine and everolimus is safe and feasible, with potential activity in pancreatic cancer patien...

journal_title：Cancer chemotherapy and pharmacology

authors： Kordes S,Klümpen HJ,Weterman MJ,Schellens JH,Richel DJ,Wilmink JW

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:This study was performed to determine whether or not in cervical, ovarian and lung cancer cell lines, free radicals (ROS) play a role in cisplatin cytotoxicity and activation of the mitochondrial and JNK/p38 pathways. The role of the enzyme, dihydrodiol dehydrogenase (DDH1), in the activation/deactivation of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen J,Solomides C,Parekh H,Simpkins F,Simpkins H

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC). This randomized, multicenter, phase II study compared the activities and safeties of the oral fluoropyrimidines, capecitabine and S-1, in breast cancer patients. METHODS:Patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto D,Iwase S,Tsubota Y,Ariyoshi K,Kawaguchi T,Miyaji T,Sueoka N,Yamamoto C,Teramoto S,Odagiri H,Kitamura K,Nagumo Y,Yamaguchi T

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:This study was performed to evaluate the safety and determine the recommended dose (RD) of resminostat monotherapy, an oral histone deacetylase (HDAC) inhibitor, in Japanese patients with advanced solid tumors. METHODS:Resminostat was administered to patients with advanced solid tumors on a 14-day cycle consis...

journal_title：Cancer chemotherapy and pharmacology

authors： Kitazono S,Fujiwara Y,Nakamichi S,Mizugaki H,Nokihara H,Yamamoto N,Yamada Y,Inukai E,Nakamura O,Tamura T

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:A recirculating isolated perfused rat liver model was used to investigate the hepatobiliary disposition of etoposide and the effects of cyclosporine A (CyA) on the pattern of drug disposition in the bile and uptake in the liver. METHODS:The portal vein, bile duct, and superior vena cava were cannulated in four...

journal_title：Cancer chemotherapy and pharmacology

authors： Khezrian M,Sheikholeslami B,Dadashzadeh S,Lavasani H,Rouini M

更新日期：2015-05-01 00:00:00

abstract：:Macroautophagy is widely accepted as a cytoprotective mechanism against various environmental stresses. While inhibition of autophagy is generally considered to increase the susceptibility of cancer cells to therapeutic agents, whether it also plays a similar role in tumor stem cells is unclear and still controversial...

journal_title：Cancer chemotherapy and pharmacology

authors： Lin YH,Huang YC,Chen LH,Chu PM

更新日期：2015-05-01 00:00:00

abstract：PURPOSE:Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this st...

journal_title：Cancer chemotherapy and pharmacology

authors： Nio K,Arita S,Isobe T,Kusaba H,Kohashi K,Kajitani T,Tamura S,Hirano G,Mitsugi K,Makiyama A,Esaki T,Ariyama H,Oda Y,Akashi K,Baba E

更新日期：2015-04-01 00:00:00